Scott W. Lowe
Impact in
- Cancer Research top 0.01%
- MicroRNA in disease regulation
- Oncology top 0.01%
- Cancer-related Molecular Pathways
Papers in
-
- Cell death mechanisms and regulation 32
- CRISPR and Genetic Engineering 32
- RNA Interference and Gene Delivery 31
- RNA modifications and cancer 30
- Epigenetics and DNA Methylation 29
- Protein Degradation and Inhibitors 29
- Oncology 132
- Cancer-related Molecular Pathways 93
- Co-authors
- Tyler Jacks (11 shared papers)Athena W. Lin (7 shared papers)Gregory J. Hannon (24 shared papers)David E. Housman (5 shared papers)Carlos Cordon‐Cardo (18 shared papers)Jordan S. Fridman (7 shared papers)H. Earl Ruley (4 shared papers)Elisa de Stanchina (29 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (30 papers)Nature (28 papers)Cell (23 papers)Blood (22 papers)Genes & Development (22 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Scott W. Lowe
322 papers receiving 70.4k citations
Scott W. Lowe's Hit Papers
Peers
Comparison fields: 5 of 184
- Cancer Research 15.7k
- Oncology 21.4k
- Molecular Biology 47.7k
- Aging 1.2k
- Biotechnology 3.7k
Countries citing papers authored by Scott W. Lowe
This map shows the geographic impact of Scott W. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott W. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott W. Lowe more than expected).
Fields of papers citing papers by Scott W. Lowe
This network shows the impact of papers produced by Scott W. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott W. Lowe. The network helps show where Scott W. Lowe may publish in the future.
Co-authors
The 25 scholars most cited alongside Scott W. Lowe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 325 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A microRNA polycistron as a potential human oncogene Hit paper breakdown → | 2005 | 2876 |
| 2 | p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Hit paper breakdown → | 1993 | 2546 |
| 3 | p53 is required for radiation-induced apoptosis in mouse thymocytes Hit paper breakdown → | 1993 | 2484 |
| 4 | A microRNA component of the p53 tumour suppressor network Hit paper breakdown → | 2007 | 2177 |
| 5 | Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours Hit paper breakdown → | 1996 | 1930 |
| 6 | Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas Hit paper breakdown → | 2007 | 1921 |
| 7 | Apoptosis Hit paper breakdown → | 2002 | 1909 |
| 8 | Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence Hit paper breakdown → | 2003 | 1755 |
| 9 | Apoptosis in cancer Hit paper breakdown → | 2000 | 1570 |
| 10 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Hit paper breakdown → | 2011 | 1447 |
| 11 | Putting p53 in Context Hit paper breakdown → | 2017 | 1395 |
| 12 | p53 Status and the Efficacy of Cancer Therapy in Vivo Hit paper breakdown → | 1994 | 1251 |
| 13 | Control of apoptosis by p53 Hit paper breakdown → | 2003 | 1148 |
| 14 | Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo Hit paper breakdown → | 1998 | 1105 |
| 15 | Reversal of human cellular senescence: roles of the p53 and p16 pathways Hit paper breakdown → | 2003 | 1104 |
| 16 | Intrinsic tumour suppression Hit paper breakdown → | 2004 | 1005 |
| 17 | The microcosmos of cancer Hit paper breakdown → | 2012 | 921 |
| 18 | Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach Hit paper breakdown → | 2006 | 864 |
| 19 | A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy Hit paper breakdown → | 2002 | 845 |
| 20 | Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy Hit paper breakdown → | 2004 | 794 |
About Scott W. Lowe
Scott W. Lowe is a scholar working on Molecular Biology, Oncology, Cancer Research, Immunology and Hematology, having authored 325 papers that have together received 71.5k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (93 papers), Cell death mechanisms and regulation (32 papers), Acute Myeloid Leukemia Research (32 papers), CRISPR and Genetic Engineering (32 papers), RNA Interference and Gene Delivery (31 papers), RNA modifications and cancer (30 papers), Epigenetics and DNA Methylation (29 papers) and Protein Degradation and Inhibitors (29 papers). The work is most often cited by research in Cancer Research (15.7k citations), Oncology (21.4k citations), Molecular Biology (47.7k citations), Aging (1.2k citations) and Biotechnology (3.7k citations). Scott W. Lowe has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Tyler Jacks, Athena W. Lin, Gregory J. Hannon, David E. Housman, Carlos Cordon‐Cardo, Jordan S. Fridman, H. Earl Ruley, Elisa de Stanchina, Edward R. Kastenhuber and Lars Zender. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature, Cell, Blood and Genes & Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.